Moderna taps biotech legend Henri Termeer for board of directors

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.

Biotech legend Termeer joins Moderna board

Henri Termeer has joined Moderna Therapeutics' board of directors. Termeer served as chairman, president and CEO of Genzyme for nearly three decades. "It is an exciting time to be joining the board of Moderna, which I believe has the potential to transform the way in which protein therapeutics are developed, and to address diseases that are not currently reachable by recombinant technologies," Termeer said in a statement. "Moderna shares the same vision, ambition, and potential as many of the early biotechnology leaders. I look forward to helping the company deliver on its vast potential to improve the lives of patients across a wide array of disease areas." Release

Moderna Therapeutics
Henri A. Termeer has joined Moderna Therapeutics' board of directors.

Eddie Gray was named the new CEO of Dynavax Technologies.


Dynavax Technologies ($DVAX) has tapped GlaxoSmithKline's ($GSX) Eddie Gray as CEO. Story | Release

Afraxis has appointed Carmine Stengone as president and CEO and Christopher Rex as chief scientific officer. Stengone helped establish Afraxis as a spin-out from Afraxis Holdings, and Rex currently leads scientific operations at Afraxis. Release

Eva-Lotta Allan has been appointed to U.K.-based Immunocore's board of directors as chief business officer. Previously, Allan was with Ablynx NV, where she served as chief business officer since 2006. Release

Smart Therapeutics ($BSX) has appointed Johns Abeles to its advisory board. Previously, Abeles was a senior medical executive with Sterling Drug, Pfizer ($PFE) and Revlon Healthcare. Release

Celsion ($CLN) has added Fredric Price to its board of directors. Price was most recently the chairman and CEO of Chiasma. Release

Medivation ($MDVN) has elected Wendy Yarno, formerly of Merck ($MRK), to its board of directors. Release

Vivus ($VVUS) has appointed Robert Wilson to its board of directors. Wilson previously served in several roles at Johnson & Johnson ($JNJ). Release

Metamark Genetics has appointed Shawn Marcell president and CEO. Most recently, he was the lead executive, serving as general manager of Hologic's ($HOLX) LIFECODES subsidiary. Release

> BioDelivery Sciences International ($BDSI) brought on Thomas W. D'Alonzo as a member of the company's board of directors. D'Alonzo previously served on the board from 2006 to 2008. Release

Jessie Lai-Sim Au joined Actium Biosystems as a member of the company's scientific advisory board. She was most recently a distinguished professor in the School of Pharmacy at The Ohio State University. Release

PDL BioPharma ($PDLI) appointed Peter Garcia as chief financial officer. Garcia's last CFO position was at BioTime ($BTX). Release

Carole Gabos and Jeremie Braun joined Novella Clinical as directors of client business development. Release

Celsus Therapeutics appointed Robert F. Doman as a member of its board of directors. Doman was president and CEO of DUSA Pharmaceuticals, specializing in dermatology. Release

Ultragenyx brought on Eric Yuen as its chief medical officer and senior vice president. Yuen comes from Janssen Alzheimer Immunotherapy R&D, a Johnson & Johnson ($JNJ) affiliate. Release

Mylan ($MYL) appointed the FDA's former commissioner for global regulatory operations and policy, Deborah Autor, as its senior vice president, Strategic Global Quality and Regulatory Policy. Autor was at FDA for 11 years. Release

Sanuwave named Daniel Jorgensen its chief medical officer, where he will help develop dermaPACE, a diabetic foot ulcer treatment. Story


Dave Lemus was bumped up from chief operating officer to CEO at Sigma-Tau Pharmaceuticals. He is the first CEO of the company. Release

A.P. Pharma's board of directors has appointed a new management team to lead the company. Barry Quart will join the company as CEO; Robert Rosen, senior vice president and chief commercial officer, will be promoted to president; and Steve Davis will join the company as executive vice president and chief operating officer. Release

Ohr Pharmaceutical has appointed Thomas Riedhammer--most recently chairman of Sirion Therapeutics--to its board of directors. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.